|
Video: What is a Stock Split?
|
|
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat neurologically mediated conditions. Co. is developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Haduvio is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and m-opioid receptor antagonist. According to our Trevi Therapeutics stock split history records, Trevi Therapeutics has had 0 splits. | |
|
Trevi Therapeutics (TRVI) has 0 splits in our Trevi Therapeutics stock split history database.
Looking at the Trevi Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Trevi Therapeutics shares, starting with a $10,000 purchase of TRVI, presented on a split-history-adjusted basis factoring in the complete Trevi Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/08/2019 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$8.23 |
|
End price/share: |
$2.85 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-65.37% |
|
Average Annual Total Return: |
-19.23% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,463.81 |
|
Years: |
4.96 |
|
|
|
|
|